ImpediMed Dividend

Dividend criteria checks 0/6

ImpediMed does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.5%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	AU$0
Earnings per share	-AU$0.01
Dividend yield forecast in 3Y	0%

Recent dividend updates

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08

Recent updates

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Mar 27

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08

How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Nov 25

Stability and Growth of Payments

How stable has ImpediMed's dividend per share been in the past?
Month	Dividend Per Share (annual)	Avg. Yield (%)
6/30/2025	-	0%
6/30/2024	-	0%
6/30/2023	-	0%

Stable Dividend: Insufficient data to determine if IPD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPD's dividend payments have been increasing.

Dividend Yield vs Market

ImpediMed Dividend Yield vs Market

How does IPD dividend yield compare to the market?
Segment	Dividend Yield
Company (IPD)	n/a
Market Bottom 25% (AU)	2.7%
Market Top 25% (AU)	7.5%
Industry Average (Medical Equipment)	1.5%
Analyst forecast in 3 Years (IPD)	0%

Notable Dividend: Unable to evaluate IPD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IPD has not reported any payouts.

Discover strong dividend paying companies

Strong dividend paying companies in the AU market.

ImpediMed Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Recent updates

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited, Annual General Meeting, Oct 26, 2022

Price target decreased to AU$0.22

ImpediMed Limited Announces Executive Changes

Less than half of directors are independent

ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform

No longer forecast to breakeven

ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022

New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference

No longer forecast to breakeven

Consensus revenue estimates fall by 21%

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 24% undervalued

Now 21% undervalued

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Price target increased to AU$0.32

Forecast to breakeven in 2024

Price target increased to AU$0.25

FDA Grants Breakthrough Device Designation for ImpediMed's SOZO Digital Health Platform for Renal Failure

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.02 loss per share (vs AU$0.036 loss in FY 2020)

Impedimed Announces Next Generation of Sozo® Digital Health Platform Software

ImpediMed Limited Announces Official Release of SOZO Version 4.0 Software

Consensus forecasts updated

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.026 loss in 1H 2020)

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

ImpediMed Limited to Report Q2, 2021 Results on Jan 28, 2021

ImpediMed Limited Announces PREVENT Trial Finishes ­- Final Patient Completes Follow-Up

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Impedimed Limited Announces the Publication of A New Study Demonstrating That the Company's Lymphedema Prevention Program

How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Price target raised to AU$0.19

ImpediMed Limited Secures First Commercial Heart Failure Sales

ImpediMed Limited Announces NSW Health Further Expands Lymphoedema Prevention Program

AstraZeneca Selects SOZO for Second Large Renal Trial

HFSA Poster Supports HF-Dex in the Management of HF Patients

Impedimed Limited Announces Collaboration with the Live Today Foundation to Increase Awareness and Access to Care for Cancer Patients At Risk or Suffering from Lymphedema

Impedimed Limited Announces Contract Valued at over AUD 2 Million for its SOZO Digital Health Platform to Be Used in Clinical Trial Being Conducted for AstraZeneca

ImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies Index

ImpediMed Limited Auditor Raises 'Going Concern' Doubt

Earnings released

ImpediMed Limited to Report Q4, 2020 Results on Jul 28, 2020

ImpediMed Limited announced that it has received AUD 0.227339 million in funding

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies

ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up